You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
易明醫藥(002826.SZ):與上海醫藥子公司合作經營的第三方產品瓜蔞皮注射液終止合作
格隆匯 12-24 15:52

格隆匯12月24日丨易明醫藥(002826.SZ)公佈,公司經營的第三方合作產品瓜蔞皮注射液(新通)系公司與上海醫藥子公司合作經營的品種。目前,公司與上海醫藥經過充分協商,決定終止合作,協議於2024年12月後不再續約。經過財務部門的初步測算,該產品2024年產生的營業收入預計8,500萬元,佔公司最近一期經審計的營業收入10%以上,根據《深圳證券交易所股票上市規則》及相關法規的規定,該事項達到披露標準。

該產品合作終止是基於市場環境的變化以及公司調整戰略規劃,集中資源發展自產產品,以保持自產產品的業績增長而做出的決策,是雙方經過審慎研究並協商一致的結果,不會對公司財務及經營狀況產生重大影響,不存在損害公司及中小股東權益的情形,也不影響公司未來的發展規劃。公司會進一步聚焦自產產品,推動公司持續健康發展,提升公司綜合競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account